Cardinal Health vs Cvs Health
CAH and CVS side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAH and CVS compare
Cvs Health is the larger company, worth 1.8 times as much as Cardinal Health ($115B against $64.7B).
On earnings, Cvs Health is cheaper: it trades at 10.5× trailing earnings, against 35.9× for Cardinal Health.
Cardinal Health grew revenue faster over the last twelve months (10.0% versus 6.7% for Cvs Health).
Cvs Health keeps more of each dollar of sales as profit, with a net margin of 2.6% compared with 0.71% at Cardinal Health.
Both pay dividends: Cardinal Health yields 0.74% and Cvs Health 2.2%.
Cvs Health scores higher on the StockData Score (19 against 16 for Cardinal Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAH | CVS |
|---|---|---|
| Size and price | ||
| Market cap | $64.7B | $115B |
| Share price | $278.14 | $89.79 |
| Change, 1 year | 35.8% | 12.4% |
| Change, 5 years | 474% | −3.6% |
| Beta (5Y) | 0.46 | 0.50 |
| Employees | 64K | 300K |
| StockData Score | ||
| Total score | 16 | 19 (better) |
| Valuation score | 1 | 6 (better) |
| Growth score | 4 (better) | 3 |
| Performance score | 4 | 4 |
| Health score | 3 (better) | 2 |
| Dividend score | 4 | 4 |
| Valuation | ||
| P/E | 35.9× | 10.5× (better) |
| P/S | 0.3× (better) | 0.3× |
| P/B | – | 1.4× |
| EV/EBITDA | 18.6× | 8.2× (better) |
| P/FCF | 13.2× | 7.4× (better) |
| PEG | 0.45 | – |
| FCF yield | 7.6% | 13.6% (better) |
| Fair value | $205.25 | $126.85 |
| Margin of safety | −35.5% | 29.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 10.0% (better) | 6.7% |
| Revenue growth, 5Y average | 9.4% (better) | 8.4% |
| Net income growth (TTM) | 14.0% | 2253% (better) |
| EPS growth (TTM) | 16.7% | 2158% (better) |
| EPS growth, 5Y average | 28.3% (better) | −23.9% |
| Profitability | ||
| Gross margin | 3.9% | 44.2% (better) |
| Operating margin | 1.0% | 3.6% (better) |
| Net margin | 0.71% | 2.6% (better) |
| FCF margin | 1.9% | 3.7% (better) |
| Return on equity | – | 14.4% |
| Return on invested capital | 206% (better) | 10.8% |
| Financial health | ||
| Debt / equity | – | 0.75 |
| Net debt / EBITDA | 0.97 (better) | 2.34 |
| Interest coverage | 7.9× (better) | 4.9× |
| Current ratio | 0.88 (better) | 0.85 |
| Altman Z-score | 5.05 (better) | 2.51 |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.74% | 2.2% (better) |
| Payout ratio | 26.8% | 31.0% |
| Years of dividend growth | 17 (better) | 0 |
| Dividend growth, 5Y average | 1.0% | 5.9% (better) |
| Buyback yield | 2.3% | – |
| Shareholder yield | 3.0% (better) | 2.2% |
| Ownership | ||
| Held by institutions | 88.7% | 89.2% |
| Held by insiders | 0.28% | 0.43% |
| Insider net buying, 12 months | −$61.6M (better) | −$322M |
| Superinvestors holding | 2 | 6 (better) |
| Short interest, % of float | 3.3% | 1.4% |
Go deeper
- CAH stock overview
- CAH income statement
- CAH valuation and score
- CVS stock overview
- CVS income statement
- CVS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.